REFRACTORY MELANOMA
Clinical trials for REFRACTORY MELANOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MELANOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: trial targets a key genetic driver
Disease control OngoingThis study is testing a drug called tipifarnib in children and young adults whose advanced cancers have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug as a pill or through a fee…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Last-Chance drug access for advanced melanoma patients
Disease control NO_LONGER_AVAILABLEThis was a compassionate use program, which allowed continued access to an investigational drug called vidutolimod for patients with melanoma that had stopped responding to other treatments. It was only available to a very specific group of people who had already been receiving t…
Matched conditions: REFRACTORY MELANOMA
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New combo attack on deadly melanoma brain tumors
Disease control OngoingThis study is testing whether combining the drugs Avastin and Tencentriq, with or without a third drug called Cotellic, can help control melanoma that has spread to the brain. It is for adults with this specific type of advanced skin cancer who have not yet received treatment for…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists test new Cancer-Fighting duo in early trial
Disease control OngoingThis early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs …
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC